6533b82efe1ef96bd1292a07
RESEARCH PRODUCT
Single-centre, triple-blinded, randomised, 1-year, parallel-group, superiority study to compare the effects of Roux-en-Y gastric bypass and sleeve gastrectomy on remission of type 2 diabetes and β-cell function in subjects with morbid obesity: a protocol for the Obesity surgery in Tønsberg (Oseberg) study
Dag HofsøTor Olav Widerøe HillestadHeidi BorgeraasTor-ivar KarlsenTone Gretland ValderhaugMorten LindbergRune SandbuJolanta LorentzenJens Kristoffer HertelMarius SvanevikKåre I. BirkelandJøran HjelmesæthErling HalvorsenRonette L. KolotkinFarhat FatimaNils Petter KvanNjord NordstrandBirgitte SeipLine Kristin JohnsonHanne L. GulsethKathrine Aglen SeebergJohn Olav Grimnessubject
Malemedicine.medical_specialtySleeve gastrectomyβ-cell functionmedicine.medical_treatment1843Gastric BypassBariatric Surgery030209 endocrinology & metabolismType 2 diabeteslaw.invention03 medical and health sciences0302 clinical medicineSuperiority TrialRandomized controlled trialClinical ProtocolslawGastrectomyDiabetes mellitusInternal medicineInsulin-Secreting CellsmedicineProtocolHumans030212 general & internal medicine1506VDP::Medisinske Fag: 700::Klinisk medisinske fag: 750::Kardiologi: 771Glycated Hemoglobinbusiness.industryNorwayGeneral Medicinemedicine.diseaseRoux-en-Y anastomosismorbid obesityObesity MorbidDiabetes and EndocrinologyTreatment OutcomeDiabetes Mellitus Type 2GastrectomyFemaleLaparoscopytype 2 diabetesbusinessEpidemiologic MethodsBody mass indexrandomised controlled trialsleeve gastrectomydescription
IntroductionBariatric surgery is increasingly recognised as an effective treatment option for subjects with type 2 diabetes and obesity; however, there is no conclusive evidence on the superiority of Roux-en-Y gastric bypass or sleeve gastrectomy. The Oseberg study was designed to compare the effects of gastric bypass and sleeve gastrectomy on remission of type 2 diabetes and β-cell function.Methods and analysisSingle-centre, randomised, triple-blinded, two-armed superiority trial carried out at the Morbid Obesity Centre at Vestfold Hospital Trust in Norway. Eligible patients with type 2 diabetes and obesity were randomly allocated in a 1:1 ratio to either gastric bypass or sleeve gastrectomy. The primary outcome measures are (1) the proportion of participants with complete remission of type 2 diabetes (HbA1c≤6.0% in the absence of blood glucose-lowering pharmacologic therapy) and (2) β-cell function expressed by the disposition index (calculated using the frequently sampled intravenous glucose tolerance test with minimal model analysis) 1 year after surgery.Ethics and disseminationThe protocol of the current study was reviewed and approved by the regional ethics committee on 12 September 2012 (ref: 2012/1427/REK sør-øst B). The results will be disseminated to academic and health professional audiences and the public via publications in international peer-reviewed journals and conferences. Participants will receive a summary of the main findings.Trial registration numberNCT01778738;Pre-results.
year | journal | country | edition | language |
---|---|---|---|---|
2019-06-01 |